 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

In trading on Thursday, shares of Oric Pharmaceuticals Inc (ORIC) crossed below their 200 day moving average of 6.21, changing hands as low as 5.97 per share. Oric Pharmaceuticals Inc...

Notable Two Hundred Day Moving Average Cross - ORIC

This is a signal that ORIC's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Oric Pharmaceuticals (ORIC, $7.04) RSI Indicator left the oversold zone on September 26, 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Oric Pharmaceuticals initiated with an Outperform at Wedbush

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

Oric Pharmaceuticals price target raised to $13 from $8 at Citi

SOUTH SAN FRANCISCO and SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following ...

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

In a report released yesterday, Colleen M. Kusy from Robert W. Baird reiterated a Buy rating on Oric Pharmaceuticals (ORIC Research Report), with... In a report released yesterday, Colleen M. Kusy from Robert W. Baird reiterated a Buy rating on Oric Pharmaceuticals (ORIC &#8211...

Oric Pharmaceuticals (ORIC) Receives a Buy from Robert W. Baird

Oric Pharmaceuticals price target lowered to $13 from $14 at H.C. Wainwright

ORIC Pharmaceuticals GAAP EPS of -$0.50 beats by $0.08

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Watchers	508
52-Wk Low	$2.36
52-Wk High	$9.79

Market Cap	$321.2M
Volume (M)	559,917.00
52-Wk High	$9.79
52-Wk Low	$2.36

ORIC ORIC Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals